biomedical research

The HealthAdvance Fund®

Advancing Biomedical Innovations

Advancing Biomedical Innovations

As part of the Rutgers Optimizes Innovation initiative, HealthAdvance Fund® provides commercialization funding to assist the development of early-stage life sciences technologies and make them more attractive for continued follow-on investments from industry partners and external investors.

About the Rutgers HealthAdvance Fund®

HealthAdvance Fund® is the funding platform of Rutgers Optimizes Innovation (ROI) program established with a $4 million grant received under the National Institutes of Health (NIH) Research Evaluation And Commercialization Hub (REACH). The program aims to energize the innovation culture across all university campuses to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics, and tools to improve health and patient care and train the next generation of innovators. 

Illustration of stethoscope on top of heartbeat sinus wave

Pre-Qualification Guidelines & Form

Find out more about eligibility and application requirements for pre-qualification and the application process and timeline.

A close-up of a monthly calendar

Meet the Mentors-in-Residence

Our Mentors-in-Residence (MIRs) are individually matched to the Innovator teams that have been invited to submit a full application to the program and collaborate with their matched Innovators to craft compelling proposals for a commercially viable product or solution, with a strong focus on improving human health.

A light bulb hanging with the word Mentor lit up inside

Contact the Team

Recently Funded Projects

Visual description of Nervana technology

The proposed technology will repair peripheral nerve injuries (PNI) by utilizing a biodegradable biopolymer scaffold enclosing a hydrogel-peptide matrix-based 3Dsystem combined with cultured autologous human cells to augment nerve growth once implanted.


Tuberculosis is characterized by 10 million cases and 1.5 million deaths per year. New drugs are needed to reduce treatment duration and to treat drug-resistant infections. We propose a solution based on our preclinical drug lead (JSF-3285) that inhibits the essential ß-ketoacyl synthase and exhibits promising efficacy and safety profiles.